Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy.
Gabriella BrömsHelle KielerAnders EkbomGissler MikaKarin HellgrenMaarit K LeinonenLars PedersenMarcus Schmitt-EgenolfHenrik Toft SorensenFredrik GranathPublished in: Alimentary pharmacology & therapeutics (2020)
Both anti-TNF and non-biologic systemic treatment were associated with an increased risk of paediatric infections. However, reassuringly, the increased risks were present regardless of treatment in the third trimester, or with combination treatment, and were not persistent during the first 3 years of life. Our findings may indicate a true risk, but could also be due to unadjusted confounding by disease severity and healthcare-seeking behaviour. This may in turn shift the risk-benefit equation towards continuation of treatment even in the third trimester.